ATE552260T1 - Substituierte porphyrine und deren therapeutische verwendung - Google Patents

Substituierte porphyrine und deren therapeutische verwendung

Info

Publication number
ATE552260T1
ATE552260T1 AT05014279T AT05014279T ATE552260T1 AT E552260 T1 ATE552260 T1 AT E552260T1 AT 05014279 T AT05014279 T AT 05014279T AT 05014279 T AT05014279 T AT 05014279T AT E552260 T1 ATE552260 T1 AT E552260T1
Authority
AT
Austria
Prior art keywords
therapeutic use
substituted porphyrins
oxidants
relates
processes
Prior art date
Application number
AT05014279T
Other languages
English (en)
Inventor
James D Crapo
Brian J Day
Michael P Trova
Polivini Jolicia F Gauunm
Douglas B Kitchen
Irwin Fridovich
Ines Batinic-Haberle
Original Assignee
Nat Jewish Health
Aeolus Sciences Inc
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Jewish Health, Aeolus Sciences Inc, Univ Duke filed Critical Nat Jewish Health
Application granted granted Critical
Publication of ATE552260T1 publication Critical patent/ATE552260T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B47/00—Porphines; Azaporphines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT05014279T 1999-01-25 2000-01-25 Substituierte porphyrine und deren therapeutische verwendung ATE552260T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11701099P 1999-01-25 1999-01-25

Publications (1)

Publication Number Publication Date
ATE552260T1 true ATE552260T1 (de) 2012-04-15

Family

ID=22370524

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00905776T ATE312103T1 (de) 1999-01-25 2000-01-25 Substituierte porphyrine und deren therapeutische verwendungen
AT05014279T ATE552260T1 (de) 1999-01-25 2000-01-25 Substituierte porphyrine und deren therapeutische verwendung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT00905776T ATE312103T1 (de) 1999-01-25 2000-01-25 Substituierte porphyrine und deren therapeutische verwendungen

Country Status (18)

Country Link
US (7) US6544975B1 (de)
EP (3) EP2295435A1 (de)
JP (1) JP4501128B2 (de)
KR (1) KR100753184B1 (de)
CN (1) CN1156478C (de)
AT (2) ATE312103T1 (de)
AU (1) AU779283B2 (de)
BR (1) BR0007720B1 (de)
CA (1) CA2359116C (de)
DE (1) DE60024588T2 (de)
DK (2) DK1155019T3 (de)
ES (2) ES2385486T3 (de)
HK (2) HK1047744A1 (de)
IL (3) IL144503A0 (de)
MX (1) MXPA01007451A (de)
NZ (1) NZ513164A (de)
WO (1) WO2000043395A1 (de)
ZA (1) ZA200106107B (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747026A (en) * 1993-10-15 1998-05-05 University Of Alabama At Birmingham Research Foundation Antioxidants
US6127356A (en) 1993-10-15 2000-10-03 Duke University Oxidant scavengers
DE69813898T2 (de) * 1997-11-03 2004-03-11 Duke University Substituierte porphyrinen
WO1999055388A1 (en) 1998-04-24 1999-11-04 Duke University Substituted porphyrins
DE60024588T2 (de) 1999-01-25 2006-08-17 National Jewish Medical And Research Center, Denver Substituierte porphyrine und deren therapeutische verwendungen
FR2806911B1 (fr) * 2000-03-28 2003-01-10 Univ Rene Descartes Utilisation de mimetiques de la sod dans le traitement d'insuffisances hepatocellulaires
US20030069281A1 (en) * 2000-06-14 2003-04-10 Irwin Fridovich Tetrapyrroles
JP2004520380A (ja) 2001-01-19 2004-07-08 ナショナル・ジュウィッシュ・メディカル・アンド・リサーチ・センター 癌治療本出願は、２００１年１月１９日に出願の仮出願番号第６０／２６２，３９０号の優先権を主張し、その全ての内容は、参照により本願明細書に援用したものとする。
US7071189B2 (en) * 2001-04-27 2006-07-04 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compound and antitumor agent containing the same as active ingredient
WO2002098431A1 (en) * 2001-06-01 2002-12-12 National Jewish Medical And Research Center Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance
US20030086916A1 (en) * 2001-10-12 2003-05-08 Goligorsky Michael S. Use of peroxynitrite scavengers or peroxynitrite formation inhibitors that do not diminish nitric oxide synthesis or activity to reverse or prevent premature vascular senescence
WO2003103680A1 (en) * 2002-06-07 2003-12-18 Duke University Substituted porphyrins
US20040127479A1 (en) * 2002-08-27 2004-07-01 Merck Patent Gmbh Peroxynitrite rearrangement catalysts
US20040116403A1 (en) * 2002-12-06 2004-06-17 Klimko Peter G. Superoxide dismutase mimics for the treatment of ocular disorders and diseases
GB2397067B (en) * 2002-12-23 2005-05-11 Destiny Pharma Ltd Porphin & azaporphin derivatives with at least one cationic-nitrogen-containing meso-substituent for use in photodynamic therapy & in vitro sterilisation
EP1452175A1 (de) * 2003-02-28 2004-09-01 Medesis Pharma S.A. Organometallische Komplexe entahltend Mangan, pharmazeutische Formulierungen und Diätetika
US20080161255A1 (en) * 2003-05-29 2008-07-03 Michael Brownlee Use of Parp Inhibitors for Prevention and Treatment of Diabetic and Insulin Resistance Complications
US7299082B2 (en) 2003-10-31 2007-11-20 Abbott Diabetes Care, Inc. Method of calibrating an analyte-measurement device, and associated methods, devices and systems
US8165651B2 (en) 2004-02-09 2012-04-24 Abbott Diabetes Care Inc. Analyte sensor, and associated system and method employing a catalytic agent
US7807825B2 (en) 2004-02-09 2010-10-05 Duke University Substituted porphyrins
US7699964B2 (en) 2004-02-09 2010-04-20 Abbott Diabetes Care Inc. Membrane suitable for use in an analyte sensor, analyte sensor, and associated method
BRPI0509359A (pt) 2004-03-29 2007-09-04 Inotek Pharmaceuticals Corp compostos de porfirina substituìda por piridila e métodos de empregos destes
GB2415372A (en) 2004-06-23 2005-12-28 Destiny Pharma Ltd Non photodynamical or sonodynamical antimicrobial use of porphyrins and azaporphyrins containing at least one cationic-nitrogen-containing substituent
WO2006037050A2 (en) * 2004-09-24 2006-04-06 Metaphore Pharmaceuticals, Inc. Methods for treating congestive heart failure
GB0424294D0 (en) * 2004-11-03 2004-12-01 Elam T Ltd Buffer layer
US7582751B2 (en) * 2005-07-29 2009-09-01 North Carolina State University Methods and intermediates for the synthesis of porphyrins
US7501508B2 (en) * 2005-07-29 2009-03-10 North Caroline State University Methods and intermediates for the synthesis of porphyrins
US7885698B2 (en) 2006-02-28 2011-02-08 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
US20090018094A1 (en) * 2006-12-01 2009-01-15 Loma Linda University Medical Center Inhibition of brain enzymes involved in cerebral amyloid angiopathy and macular degeneration
US20080289053A1 (en) * 2007-05-15 2008-11-20 The Regents Of The University Of California Methods and systems for identifying modulators of longevity
WO2009004339A2 (en) * 2007-07-03 2009-01-08 Imperial Innovations Limited Compositions and methods relating to manipulation of the myeloid immune compartment during respiratory infection
US8791099B2 (en) * 2007-08-28 2014-07-29 Technion Research And Development Foundation Ltd. Transition metal complexes of corroles for preventing cardiovascular diseases or disorders
US8598150B1 (en) 2008-04-02 2013-12-03 Jonathan R. Brestoff Composition and method for affecting obesity and related conditions
US8987245B2 (en) 2008-04-02 2015-03-24 Jonathan R. Brestoff Parker Composition and method for affecting obesity and related conditions
MX2010012593A (es) * 2008-05-23 2011-03-04 Nat Jewish Health Metodos para el tratamiento de lesion asociada con exposicion a especie alcalina.
CA2762474A1 (en) * 2009-05-26 2010-12-02 Duke University Method of providing neuroprotection using substituted porphyrins
WO2011028935A2 (en) * 2009-09-02 2011-03-10 The Regents Of The University Of Colorado Methods of treating mitochondrial disorders using metalloporhyrins
DK2625180T3 (en) * 2010-10-06 2016-06-06 Aeolus Sciences Inc Porphyrinbehandling neurodegenerative diseases
WO2012105483A1 (ja) * 2011-01-31 2012-08-09 国立大学法人宇都宮大学 ポルフィリン型骨格を有する化合物の金属錯体の製造方法
KR20140109386A (ko) 2011-12-02 2014-09-15 더 리전츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코퍼레이트 금속포르피린 신경 치료
CN102775415B (zh) * 2012-07-10 2014-10-22 西北大学 一种卟啉的合成方法
WO2014028823A1 (en) * 2012-08-16 2014-02-20 Leading Energy Designs, Ltd. Led bracket apparatus for high-output led lighting systems
JP6244004B2 (ja) 2013-03-14 2017-12-06 プロフサ，インコーポレイテッド 酸素センサ
WO2015034778A1 (en) * 2013-09-03 2015-03-12 Biomimetix J.V., Llc Methods of treating erectile dysfunction
WO2015077627A1 (en) * 2013-11-22 2015-05-28 Aeolus Sciences, Inc. Synthesis and formulations of porphyrin compounds
CA2933166C (en) 2013-12-31 2020-10-27 Abbott Diabetes Care Inc. Self-powered analyte sensor and devices using the same
WO2015112588A1 (en) * 2014-01-22 2015-07-30 Biomimetix Jv, Llc Methods of treating skin disorders
WO2015112586A1 (en) 2014-01-22 2015-07-30 Duke University Methods of treating pruritus
AT516549B1 (de) * 2014-11-20 2017-05-15 Wenatex Forschung - Entw - Produktion Gmbh Antimikrobielles Mittel zum biociden Ausrüsten von Polymeren
EP3365349B1 (de) 2015-08-18 2022-06-15 University of Pittsburgh- Of the Commonwealth System of Higher Education Viologen-funktionalisierte porphyrine zur verringerung von bewuchs auf flächen
CA3046357A1 (en) * 2016-12-20 2018-06-28 Duke University Methods of making substituted porphyrin pharmaceutical compounds and compositions
EP3558118A4 (de) 2016-12-21 2021-02-24 Profusa, Inc. Polymerisierbare nahinfrarot-farbstoffe
CN110028514B (zh) * 2019-05-30 2021-07-02 湖南科技大学 5,10,15,20-四芳基-2,3-咪唑稠合-21-碳叶绿素化合物及制备方法
CA3143430A1 (en) * 2019-06-14 2020-12-17 Universidade De Coimbra Small cationic ortho-5,15-di-heteroaryl-porphyrins derivatives and their applications in photoinactivation of microorganisms
CN116284017B (zh) * 2023-03-27 2024-03-22 中国科学院青岛生物能源与过程研究所 一种利用仿酶高效催化氧化制备酰胺化合物的方法

Family Cites Families (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US437221A (en) * 1890-09-30 Circular-saw-smithing machine
US2951799A (en) * 1957-11-13 1960-09-06 Monsanto Chemicals Photoxidation processes using heterocyclic photosensitizers
JPS5641611B2 (de) * 1973-04-19 1981-09-29
DE3464252D1 (en) 1983-06-03 1987-07-23 Hoffmann La Roche Labelled molecules for fluorescence immunoassays and processes and intermediates for their preparation
US4829984A (en) * 1983-12-15 1989-05-16 Gordon Robert T Method for the improvement of transplantation techniques and for the preservation of tissue
US4963367A (en) 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US5087438A (en) * 1984-07-03 1992-02-11 Gordon Robert T Method for affecting intracellular and extracellular electric and magnetic dipoles
US4911920A (en) * 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
GB8429845D0 (en) 1984-11-26 1985-01-03 Efamol Ltd Porphyrins & cancer treatment
US4758422A (en) 1985-01-04 1988-07-19 Salutar Inc. Ferrioxamine paramagnetic contrast agents for MR imaging
US4657902A (en) 1985-03-25 1987-04-14 The Rockefeller University Therapeutic use of tin mesoporphyrin
DE3686025T2 (de) 1985-05-22 1993-01-07 Liposome Technology Inc Verfahren und system zum einatmen von liposomen.
DK402785D0 (da) 1985-09-03 1985-09-03 Syn Tek Ab Fremgangsmaade til fremstilling af et enzym
US5248603A (en) 1985-09-03 1993-09-28 Symbicom Aktiebolag Superoxide dismutase
FR2588189B1 (fr) * 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
US4866054A (en) * 1986-05-13 1989-09-12 Chai-Tech Corporation Antioxidant metallo-organic treatment of inflammation
US4746735A (en) 1986-11-21 1988-05-24 The Dow Chemical Company Regiospecific aryl nitration of meso-substituted tetraarylporphyrins
US5162231A (en) 1989-10-25 1992-11-10 Cole Dean A Method of using 5,10,15,20-tetrakis(carboxyphenyl)porphine for detecting cancers of the lung
EP0676472A1 (de) 1987-03-14 1995-10-11 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Humane Mangan-Superoxiddismutase (hMn-SOD)
DE3800973C2 (de) * 1987-03-25 1992-03-19 Degussa Ag, 6000 Frankfurt, De Oxowolfram(v)-porphyrin-komplexe wo(p)x
US5227405A (en) 1987-03-31 1993-07-13 Duke University Superoxide dismutase mimic
US5223538A (en) 1987-03-31 1993-06-29 Duke University Superoxide dismutase mimic
US4892941A (en) 1987-04-17 1990-01-09 Dolphin David H Porphyrins
US4851403A (en) 1987-04-21 1989-07-25 Johnson Matthey, Inc. Radiation sensitizers
US4885114A (en) 1987-04-22 1989-12-05 Barnes Engineering Co. Metallized tetra((meso)-5-methyl-2-thiophene)porphines, platinum (5-bromo octaethylporphine) and optical filters containing same
US5051337A (en) 1987-06-10 1991-09-24 Director-General Of Agency Of Industrial Science And Technology Optical recording material
DE3805697A1 (de) * 1988-02-24 1989-09-07 Bayer Ag Verfahren zur herstellung von p-hydroxy-benzaldehyden
GB8805849D0 (en) 1988-03-11 1988-04-13 Efamol Holdings Porphyrins & cancer treatment
US5162519A (en) 1988-03-11 1992-11-10 Efamol Holdings Plc Porphyrins and cancer treatment
DE3809671A1 (de) 1988-03-18 1989-09-28 Schering Ag Porphyrin-komplexverbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
US5284647A (en) 1988-03-18 1994-02-08 Schering Aktiengesellschaft Mesotetraphenylporphyrin complex compounds, process for their production and pharmaceutical agents containing them
US5192788A (en) * 1988-05-23 1993-03-09 Georgia State University Foundation, Inc. Porphyrin antiviral compositions
US5109016A (en) * 1988-05-23 1992-04-28 Georgia State University Foundation, Inc. Method for inhibiting infection or replication of human immunodeficiency virus with porphyrin and phthalocyanine antiviral compositions
FR2632187B1 (fr) 1988-06-02 1990-09-14 Centre Nat Rech Scient Derives de metalloporphyrines, leur preparation, leur application en therapeutique et leur utilisation pour la preparation de molecules hybrides
US5171680A (en) 1988-06-14 1992-12-15 Chiron Corporation Superoxide dismutase analogs having novel binding properties
JPH0746212B2 (ja) 1988-12-03 1995-05-17 工業技術院長 異方性ｌｂ膜の製造法
JPH02213088A (ja) * 1989-02-13 1990-08-24 Nec Corp 有機薄膜ｅｌ素子及びその製造方法
EP0414915B1 (de) 1989-03-06 1996-06-12 Suntory Limited Neue superoxyd-dismutase
DK455789D0 (da) 1989-09-15 1989-09-15 Symbicom Ab Polypeptid
US5010073A (en) * 1989-10-05 1991-04-23 The Rockefeller University Use of liposomes as carriers for metalloporphyrins
EP0424033A3 (en) 1989-10-19 1991-07-31 Pola Chemical Industries Inc External skin preparation
US5236915A (en) 1990-05-31 1993-08-17 Health Research, Inc. Meso poly(4-sulfonatophenyl) porphines as MRI image enhancing agents
EP0462836A3 (en) 1990-06-20 1992-08-26 Mitsui Toatsu Chemicals, Inc. Recombinant vector plasmid capable of expressing human manganese superoxide dismutase, and process of producing this enzyme
US5417111A (en) * 1990-08-17 1995-05-23 Analog Devices, Inc. Monolithic chip containing integrated circuitry and suspended microstructure
US5202317A (en) 1990-09-13 1993-04-13 The Regents Of The University Of California Synthetic drug molecules that mimic metalloenzymes
US5217966A (en) 1990-09-13 1993-06-08 The Regents Of The University Of California Synthetic drug molecules that mimic metalloenzymes
WO1992007935A1 (en) 1990-11-01 1992-05-14 The Scripps Research Institute Glycosaminoglycan-targeted fusion proteins, their design, construction and compositions
CA2096333A1 (en) * 1990-11-14 1992-05-15 Joseph S. Beckman Compositions for reducing oxidative injury
US5192757A (en) 1990-12-20 1993-03-09 Glaxo Inc. Cobalt porphyrins
JP2594486B2 (ja) * 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
GB9103991D0 (en) 1991-02-26 1991-04-10 Nat Res Dev Molecular electronic devices
US5212162A (en) * 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
FR2676738B1 (fr) 1991-05-22 1995-05-05 Ir2M Nouveau derive organique de metal de transition a structure porphyrinique, composition therapeutique le contenant, en particulier a activite hypoglycemiante.
WO1993002090A1 (en) 1991-07-19 1993-02-04 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
CA2072934C (en) * 1991-07-19 2007-08-28 Karl William Aston Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
US5262532A (en) 1991-07-22 1993-11-16 E.R. Squibb & Sons, Inc. Paramagnetic metalloporphyrins as contrast agents for magnetic resonance imaging
US5212300A (en) 1991-09-12 1993-05-18 Sun Company, Inc. (R&M) Cyano- and polycyanometallo-porphyrins as catalysts for alkane oxidation
US6011146A (en) * 1991-11-15 2000-01-04 Institut Pasteur Altered major histocompatibility complex (MHC) determinant and methods of using the determinant
US5493017A (en) 1992-08-14 1996-02-20 The Trustees Of The University Of Pennsylvania Ring-metalated porphyrins
US5599924A (en) 1992-08-14 1997-02-04 Trustees Of The University Of Pennsylvania Electron-deficient porphyrins and processes and intermediates for preparing same
US5371199B1 (en) 1992-08-14 1995-12-26 Univ Pennsylvania Substituted porphyrins porphyrin-containing polymers and synthetic methods therefor
JPH08501103A (ja) 1992-09-03 1996-02-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア メタロポルフィリン組成物
US5834509A (en) 1992-12-07 1998-11-10 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US5403834A (en) * 1992-12-07 1995-04-04 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US5696109A (en) 1992-12-07 1997-12-09 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US6204259B1 (en) * 1993-01-14 2001-03-20 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
DE4305523A1 (de) 1993-02-17 1994-08-18 Diagnostikforschung Inst Meso-Tetraphenylporphyrin-Komplexverbindungen, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel
US5428037A (en) 1993-04-09 1995-06-27 Syntex Pharmaceuticals, Ltd. Heterocyclic derivatives in the treatment of Ischaemia and related diseases
JP3273082B2 (ja) 1993-06-18 2002-04-08 三和電気工業株式会社 光コネクタ用スリ−ブホルダ
JPH0743337A (ja) * 1993-07-30 1995-02-14 Toppan Printing Co Ltd マンガンポルフィリン錯体を感応物質とする陰イオン選択性電極
US6417182B1 (en) * 1993-08-25 2002-07-09 Anormed Inc. Pharmaceutical compositions comprising metal complexes
US6127356A (en) 1993-10-15 2000-10-03 Duke University Oxidant scavengers
US5747026A (en) 1993-10-15 1998-05-05 University Of Alabama At Birmingham Research Foundation Antioxidants
US5994339A (en) 1993-10-15 1999-11-30 University Of Alabama At Birmingham Research Foundation Oxidant scavengers
US5488145A (en) 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps
US5608054A (en) 1993-12-29 1997-03-04 Sun Company, Inc. (R&M) Porphyrins and metal complexes thereof having haloalkyl side chains
US5405369A (en) * 1994-01-25 1995-04-11 Medical College Of Ohio Photochemical ablation of gastro-intestinal tissue for augmentation of an organ
US5604199A (en) * 1994-03-29 1997-02-18 The Nemours Foundation Method of treating fibrosis in skeletal muscle tissue
US6245758B1 (en) * 1994-05-13 2001-06-12 Michael K. Stern Methods of use for peroxynitrite decomposition catalysts, pharmaceutical compositions therefor
EP0758892A1 (de) * 1994-05-13 1997-02-26 Monsanto Company Verfahren zur verwendung von peroxynitrit-zersetzungs-katalysatoren, pharmazeutische zusammensetzungen dafür
US5563132A (en) * 1994-06-21 1996-10-08 Bodaness; Richard S. Two-step cancer treatment method
WO1996009053A1 (en) 1994-09-20 1996-03-28 Duke University Oxidoreductase activity of manganic porphyrins
CA2132690A1 (en) 1994-09-22 1996-03-23 Dean Willis Control and modulation of inflammatory response in humans in need of such control and modulation
US6013241A (en) * 1995-01-23 2000-01-11 Schering Aktiengesellschaft Use of porphyrin-complex or expanded porphyrin-complex compounds as an infarction localization diagnosticum
IL122451A0 (en) * 1995-06-07 1998-06-15 Univ Duke Oxidant scavengers
AU6896796A (en) 1995-08-17 1997-03-12 Monsanto Company Methods of diagnostic image analysis using bioconjugates of metal complexes of nitrogen-containing macrocyclic ligands
EP0844886A2 (de) 1995-08-17 1998-06-03 Monsanto Company Biokonjugate von manganesekomplexen und die anwendung als katalysator
US5976498A (en) * 1995-08-17 1999-11-02 Neumann; William L. Methods of diagnostic image analysis using metal complexes of nitrogen-containing macrocyclic ligands
US5648523A (en) 1995-10-26 1997-07-15 Chiang Long Y Fullerene derivatives as free-radical scavengers
US5948771A (en) 1996-01-31 1999-09-07 The Trustees Of Columbia University In The City Of New York Method for treating heart failure using tetrapyrroles and metallotetrapyrroles
AU2065697A (en) 1996-03-13 1997-10-01 Monsanto Company Iron complexes of nitrogen-containing macrocyclic ligands effective as cataly sts for dismutating superoxide
JP2000508625A (ja) 1996-03-13 2000-07-11 モンサント カンパニー スーパーオキシドをジスムテートする触媒として有効な窒素含有大環状リガンドのマンガンまたは鉄錯体の生体分子結合体
JPH1062350A (ja) * 1996-08-14 1998-03-06 Ebara Corp ガス反応性色素を用いたガス検知方法及びガス検知装置
US5756492A (en) * 1996-09-09 1998-05-26 Sangstat Medical Corporation Graft survival prolongation with porphyrins
AU6650198A (en) 1997-02-05 1998-08-25 Board Of Regents, The University Of Texas System Porphyrin compounds as telomerase inhibitors
US6214817B1 (en) * 1997-06-20 2001-04-10 Monsanto Company Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity
US6180620B1 (en) * 1997-06-20 2001-01-30 G.D. Searle & Co. Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals
GB9716446D0 (en) 1997-08-05 1997-10-08 Agrevo Uk Ltd Fungicides
JP3564962B2 (ja) * 1997-08-26 2004-09-15 松下電器産業株式会社 光記録媒体及びその光記録再生方法
BR9814789A (pt) 1997-08-26 2000-10-10 Kumiai Chemical Industry Co Derivados de ácido biarilalquilenocarbamânico e fungicidas agrìcolas e hortìcolas
DE69813898T2 (de) 1997-11-03 2004-03-11 Duke University Substituierte porphyrinen
WO1999055388A1 (en) * 1998-04-24 1999-11-04 Duke University Substituted porphyrins
AU5229599A (en) 1998-07-23 2000-02-14 Metaphore, Inc. Libraries of polyhydroxamates and their analogs
WO2000023568A2 (en) 1998-10-06 2000-04-27 Albert Einstein College Of Medicine Of Yeshiva University Methods and compositions for decreasing mitochondrial overproduction of reactive oxygen species in cells
DE60024588T2 (de) * 1999-01-25 2006-08-17 National Jewish Medical And Research Center, Denver Substituierte porphyrine und deren therapeutische verwendungen
EP1185312B1 (de) 1999-05-27 2005-03-23 Monsanto Company Biomaterialien, modifiziert mit superoxid-dismutase imitatoren
US6448239B1 (en) 1999-06-03 2002-09-10 Trustees Of Princeton University Peroxynitrite decomposition catalysts and methods of use thereof
US6608050B2 (en) * 1999-07-20 2003-08-19 Pharmacia & Upjohn Company Lyophilizate of lipid complex of water insoluble porphyrins
AU1087401A (en) 1999-10-13 2001-04-23 Uab Research Foundation Metalloporphyrin treatment of neurologic disease
WO2001040233A1 (fr) * 1999-11-30 2001-06-07 Photochemical Co., Ltd. Complexe porphyrine servant de support a un nitroimidazole
JP3383839B2 (ja) * 2000-03-13 2003-03-10 奈良先端科学技術大学院大学長 新規なメルカプト置換イミダゾリルポルフィリン金属錯体単量体及びこれを繰り返し単位として有する重合体並びにこれらの製造方法
US6624187B1 (en) * 2000-06-12 2003-09-23 Health Research, Inc. Long wave length absorbing bacteriochlorin alkyl ether analogs
JP2004503556A (ja) 2000-06-14 2004-02-05 デューク・ユニバーシティー テトラピロール類
US6403788B1 (en) 2000-07-11 2002-06-11 Eukarion, Inc. Non-genotoxic metalloporphyrins as synthetic catalytic scavengers of reactive oxygen species
US6573258B2 (en) * 2000-09-27 2003-06-03 Frontier Scientific, Inc. Photodynamic porphyrin antimicrobial agents
JP2004520380A (ja) * 2001-01-19 2004-07-08 ナショナル・ジュウィッシュ・メディカル・アンド・リサーチ・センター 癌治療本出願は、２００１年１月１９日に出願の仮出願番号第６０／２６２，３９０号の優先権を主張し、その全ての内容は、参照により本願明細書に援用したものとする。
WO2002078670A1 (en) 2001-03-02 2002-10-10 Neuron Therapeutics, Inc. Neuroprotectants formulations and methods
JP2004532251A (ja) 2001-05-31 2004-10-21 ミラヴァント ファーマシューティカルズ インコーポレイテッド 光線力学療法で使用のメタロテトラピロール系光増感剤
US6566517B2 (en) * 2001-06-06 2003-05-20 Brookhaven Science Associates, Llc Metalloporphyrins and their uses as imageable tumor-targeting agents for radiation therapy
DE10240343A1 (de) 2002-08-27 2004-03-11 Schering Ag Peroxynitrit-Umlagerungskatalysatoren
US7807825B2 (en) 2004-02-09 2010-10-05 Duke University Substituted porphyrins
AU2006238888A1 (en) 2005-04-21 2006-11-02 Glenn A. Goldstein N-acetylcysteine amide (NAC amide) for the treatment of diseases and conditions associated with oxidative stress
WO2011028935A2 (en) 2009-09-02 2011-03-10 The Regents Of The University Of Colorado Methods of treating mitochondrial disorders using metalloporhyrins

Also Published As

Publication number Publication date
US6544975B1 (en) 2003-04-08
AU2740700A (en) 2000-08-07
US20070197496A1 (en) 2007-08-23
US7820644B2 (en) 2010-10-26
CN1355802A (zh) 2002-06-26
DK1155019T3 (da) 2006-04-18
EP1616869A1 (de) 2006-01-18
BR0007720B1 (pt) 2014-04-08
CN1156478C (zh) 2004-07-07
US20120214780A1 (en) 2012-08-23
IL144503A (en) 2007-10-31
DK1616869T3 (da) 2012-05-07
US8217026B2 (en) 2012-07-10
US8946202B2 (en) 2015-02-03
HK1083626A1 (en) 2006-07-07
IL183953A0 (en) 2007-10-31
ES2254142T3 (es) 2006-06-16
BR0007720A (pt) 2001-10-30
US7189707B2 (en) 2007-03-13
DE60024588D1 (de) 2006-01-12
CA2359116A1 (en) 2000-07-27
IL183953A (en) 2010-12-30
WO2000043395A1 (en) 2000-07-27
EP2295435A1 (de) 2011-03-16
CA2359116C (en) 2009-03-17
KR20010108130A (ko) 2001-12-07
US20150231150A1 (en) 2015-08-20
ZA200106107B (en) 2002-12-24
KR100753184B1 (ko) 2007-08-30
US20110065679A1 (en) 2011-03-17
EP1155019A4 (de) 2002-07-03
AU779283B2 (en) 2005-01-13
NZ513164A (en) 2006-03-31
JP2002535332A (ja) 2002-10-22
US20140011794A1 (en) 2014-01-09
IL144503A0 (en) 2002-05-23
ES2385486T3 (es) 2012-07-25
JP4501128B2 (ja) 2010-07-14
WO2000043395A8 (en) 2000-08-31
AU779283C (en) 2000-08-07
EP1155019A1 (de) 2001-11-21
HK1047744A1 (en) 2003-03-07
MXPA01007451A (es) 2004-03-10
EP1616869B1 (de) 2012-04-04
US8546562B2 (en) 2013-10-01
DE60024588T2 (de) 2006-08-17
US20040023941A1 (en) 2004-02-05
US9289434B2 (en) 2016-03-22
ATE312103T1 (de) 2005-12-15
EP1155019B1 (de) 2005-12-07

Similar Documents

Publication Publication Date Title
ATE552260T1 (de) Substituierte porphyrine und deren therapeutische verwendung
ATE311206T1 (de) Substituierte porphyrine
ATE238307T1 (de) Substituierte porphyrinen
EP1432714A4 (de) Chemische verbindungen
HK1085461A1 (en) Compounds, compositions and methods of treatment for heart failure
BE2010C030I2 (de)
DE60319406D1 (de) Meso-substituierte porphyrine
ATE555789T1 (de) Pyridazinderivate und deren verwendung als therapeutische mittel
MA28010A1 (fr) Derives de piperazine et leur utilisation comme agents therapeutiques
DE69434313D1 (de) Superoxiddismutase memetika
ATE420097T1 (de) Substituierte sapogenine und ihre verwendung
DE50208918D1 (de) 6-aminomorphinanderivate, herstellungsverfahren dafür und deren verwendung
DK0971922T3 (da) Tetrahydropyrido-forbindelser
ATE242242T1 (de) Derivate von imidazo(1,2-a)pyridin zur behandlung von gastrointestinalen krankheiten
ATE298339T1 (de) ß3,7-DIAZABICYCLO(3.3.0)OCTANE UND DEREN VERWENDUNG BEI DER BEHANDLUNG VON HERZRHYTHMUSSTÖRUNGENß
ATE343582T1 (de) Derivate von (6, 7-dihydro -5h-imidazo(1,2 - a)imidazol -3 -sulfonylamino)-propionamid und deren verwendung als inhibitoren der interaktion von cams und leukointreginen
EP1436279A4 (de) Chemische verbindungen
ID27656A (id) Turunan azabisikloheptana n-tersubstitusi, pembuatan dan penggunaannya
DE50113300D1 (de) Verwendung von erythropoietin sowie dessen derivate zur behandlung von schizophrenie und verwandten psychosen